Baylor University technology helps Acer Therapeutics raise $2.1m in funding to help those affected by Maple Syrup Urine Disease.
Acer Therapeutics, a US-based biotechnology company using technology licensed from Baylor University, has raised $2.1m.
The company is developing new treatments by using existing therapies and repurposing and reformulating them in order to treat a rare condition called Maple Syrup Urine Disease, also known as branched-chain ketoaciduria.
Acer Therapeutics, through Baylor University, currently has a phase 3 clinical trial running. The only current treatment of the disease is dietary changes and close monitoring of blood levels.
Affecting around 4000 people…
